Comparing Injections With Poly-L-Lactic Acid in the Temporal Fossa vs. Extended Temporal Fossa + Hairline

Launched by EREVNA INNOVATIONS INC. · Mar 22, 2024

Keywords

ClinConnect Summary

Non-invasive treatment of volume loss is one of the most common aesthetic treatments performed worldwide. Poly-L-lactic acid has been used as a skin filler since 1999 in Europe and since 2004 in the United States (Vlegger, 2014), as well as in several medical areas for over three decades (Chen, 2014; Vlegger, 2006) In addition, poly-L-lactic acid is widely used in several countries for facial rejuvenation, with extensive documentation of their efficacy and safety in this context (Vlegger, 2014). Sculptra® Aesthetic is an injectable implant containing microparticles of poly-L-lactic acid, ca...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects must voluntarily sign and date an informed consent, approved by an independent ethics committee, prior to the initiation of any screening or study-specific procedures.
• • Subjects must be adult male or female, at least 18 years old.
• • Subjects must be willing and able to comply with procedures required in the protocol.
• • Subjects must be in good health as per investigator's judgment based on medical history.
• • Subjects must have mild to severe temporal fossa hollowing.
• • Subjects must not have uncontrolled systemic disease.
• * Subjects do not present with or have a history of any medical condition that may place the subject at increased risk following exposure to PLLA or interfere with the study evaluation, including:
• • History of facial nerve palsy.
• • Infection or dermatological condition at the treatment injection sites.
• • Marked facial asymmetry, dermatochalasis, deep dermal scarring, excessively thick sebaceous skin, or excessively photodamaged skin.
• • Any eyebrow or eyelid ptosis at Baseline as determined by the investigator.
• • Subjects do not have history of clinically significant medical conditions or any other reason that the investigator determines would interfere with the subject's participation in this study or would make the subject an unsuitable candidate to receive study drug.
• • Subjects do not have history of an allergic reaction or significant sensitivity to constituents of the study drug (or its excipients).
• • Subjects must not have tattoos, jewelry, or clothing which obscure the temporal region and cannot be removed.
• • Subjects do not have anticipated need for surgery or overnight hospitalization during the study.
• • Subjects do not have a history of surgical procedures on forehead and/or periorbital areas or affecting these areas including any lifting procedure (e.g., facial lift, suture lift, thread lift, brow lift, eyelid and/or eyebrow surgery).
• • Subjects do not have history of periorbital or upper-facial treatment with semi- permanent or permanent soft tissue fillers (e.g., poly-L-lactic acid, polyalkylimide, polymethylmethacrylate, polytetrafluoroethylene, and silicone), synthetic implantation and/or autologous fat transplantation.
• • One month prior to enrolment: Subjects do not have any periorbital or upper-facial cosmetic procedures with superficial-to-medium resurfacing/planning (e.g., microdermabrasion, dermaplaning, dermabrasion), chemical peels (e.g., glycolic acid, trichloroacetic acid and phenol), or nonablative energy-based facial treatments (e.g., radiofrequency, ultrasound, electromagnetic, laser, light).
• • Three months prior to enrolment: Subjects do not have ablative energy-based facial treatments or permanent make-up.
• • Twelve months prior to enrolment: any periorbital or upper-facial treatment with nonpermanent soft tissue fillers (e.g., hyaluronic acid-based fillers, calcium hydroxylapatite, and collagen-based fillers).
• • Subjects with known active COVID infection within 14 days of treatment.
• • Female subjects of child-bearing potential must have a negative urine pregnancy test prior to any dose of study product.
• • Female subjects of childbearing potential must practice at least 1 protocol-specified method of birth control that is effective from Baseline through at least 30 days after the last dose or until the end of study, whichever is longer. Female subjects of non-childbearing potential do not need to use birth control.
• • Female subjects that are not pregnant or breastfeeding and are not considering becoming pregnant or donating eggs during the study or for approximately 30 days after the last dose of study drug or until the end of study, whichever is longer.
• • Subjects must not have been treated with any investigational drug within 30 days prior to the first dose of study drug or is currently enrolled in another clinical study.
• • Using or planning to initiate restrictive diets that could result in extreme fluctuations in weight (i.e., +/- 10 lbs), at investigator's discretion.
• • Using or planning to initiate the use of supplements for weight loss.
• • Using or have used within the previous 3 months drugs such as corticosteroids, immunosuppressants, anticoagulants or other collagen-production inhibitors.
• • Initiated use of hormones or change in dose of hormonal replacement therapy within 3 months, due to possible implications on weight.
• • Sculptra® Aesthetic should not be used in patients with known history of or susceptibility to keloid formation or hypertrophic scarring.